# Single-arm, Phase II Clinical Study Evaluating the Safety and Efficacy of Sintilimab Combined With IBI-310 and Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer

> **NCT07750951** · PHASE2 · RECRUITING · sponsor: **Xijing Hospital** · enrollment: 34 (estimated)

## Conditions studied

- MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma

## Interventions

- **DRUG:** Cindilimab、IBI310、Capecitabine、Oxaliplatin

## Key facts

- **NCT ID:** NCT07750951
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-29
- **Primary completion:** 2026-11
- **Final completion:** 2027-04
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2026-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07750951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07750951, "Single-arm, Phase II Clinical Study Evaluating the Safety and Efficacy of Sintilimab Combined With IBI-310 and Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07750951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*